This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Teva CNS.

This satellite symposium is neither sponsored nor endorsed by PAINWeek.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standard.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act and as such, this activity is eligible for Sunshine Act Reporting. Additional information is required to be collected from participants. If you are planning on participating in the meal, please indicate so on the evaluation and provide your NPI number.

Target Audience

The educational design of this activity addresses the needs of pain specialists, primary care providers, and other clinicians involved in opioid-based management of chronic pain.

Statement of Need/Program Overview

Affecting an estimated 100 million adults in the United States, chronic pain is among the most common reasons that patients seek medical treatment.¹ Prescription opioids are an established treatment option for functionally limiting chronic pain severe enough to require around-the-clock therapy.^2-4 Indeed, opioids are the cornerstone of cancer pain treatment,^2,3 and have gained acceptance—though not unqualified—for select patients with noncancer chronic pain.⁴ Unfortunately, increased opioid prescribing for patients in pain has been mirrored by higher rates of opioid abuse and overdose.⁴ For example, in recent years, prescription opioids have been linked to approximately three quarters of pharmaceutical overdose deaths in the United States.^4,5 To ensure patient safety and meet regulatory requirements, clinicians must adopt responsible prescribing strategies, including assessing all patients for risks related to opioid pharmacology and potential aberrant drug use.⁴ Initial risk-stratification efforts must be accompanied by appropriate follow-up monitoring and meticulous documentation of clinical decision making. Even among pain management experts, recommendations for the individualization of opioid-based regimens, incorporation of urine drug testing, and potential roles of abuse-deterrent opioid formulations continue to evolve.^6-8 During this Clinical Issues™ program, an expert faculty panel will discuss and debate guideline recommendations and newly published data on long-term opioid therapy, while providing practical advice on the growing evidence pool, risk-mitigation strategies, and regulatory requirements.

References

1. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011.
2. Swarm RA, Abernethy AP, Anghelescu DL, et al. National Comprehensive Cancer Network: Adult Cancer Pain. J Natl Compr Canc Netw. 2013;11(8):992-1022
3. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-2247.
4. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
5. Warner M, Hedegaard H, Chen L-H. Trends in Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 1999-2012. NCHS Health E-Stat. Atlanta, GA: Centers for Disease Control and Prevention/National Center for Health Statistics; 2014.
6. Peppin JF, Passik SD, Couto JE, et al. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med. 2012;13(7):886-896.
7. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351-358.
8. Simon K, Worthy SL, Barnes MC, Tarbell B. Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Ther Adv Drug Saf. 2015;6(2):67-79.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Assess candidates for chronic opioid therapy via comprehensive clinical interviews, reviews of the medical history, physical exam, and stratification of risks for drug misuse and abuse 
2. Discuss the clinical profiles of current and emerging prescription opioid analgesics, including abuse-deterrent formulations
3. Initiate opioid trials for patients with functionally impairing chronic pain severe enough to require around-the-clock, long-term therapy
4. Tailor opioid-based regimens founded on evaluations of analgesia, functional goals, side effects, and risk evaluation and mitigation strategy (REMS)–compliant principles for patient monitoring and documentation 
5. Engage in open dialogues with patients with chronic pain about actively participating in a care plan, adhering to the treatment regimen, and safely using prescription opioid analgesics

Program Agenda

11:30 AM – 12:00 PM: Registration, Meal, Preactivity Outcomes Assessment

12:00 PM – 12:05 PM: Faculty Introductions

12:05 PM – 12:30 PM: Identify Candidates for Opioid Trials

12:30 PM – 12:50 PM: Mitigation of Opioid Risks: Considering Abuse-Deterrent Formulations

12:50 PM – 1:15 PM: Challenges in Chronic Opioid Therapy: Addressing Aberrant Behavior

1:15 PM –1:30 PM: Postactivity Assessment and Question and Answer Session

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 1101021. This program has been approved for 1.5 contact hours of continuing education. (Rx hours have yet to be identified.) 

Pharmacist Accreditation Statement

Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-15-056-L01-P)

This is a knowledge-based activity.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity. For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Americas With Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Sean O’Toole prior to the live event at sotoole@integritasgrp.com